癌悪液質の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測

◆英語タイトル:Cancer Cachexia Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
◆商品コード:MOR21MR129
◆発行会社(リサーチ会社):Mordor Intelligence
◆発行日:2021年2月
◆ページ数:104
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD4,250 ⇒換算¥488,750見積依頼/購入/質問フォーム
Team User(5名利用)USD4,750 ⇒換算¥546,250見積依頼/購入/質問フォーム
Corporate License(法人利用)USD7,500 ⇒換算¥862,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMordor Intelligence社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Mordor Intelligence社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、世界の癌悪液質市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別(プロゲストーゲン、副腎皮質ステロイド、併用治療、その他)分析、作用機序別(食欲刺激剤、減量安定剤)分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の癌悪液質市場規模:治療別(プロゲストーゲン、副腎皮質ステロイド、併用治療、その他)
・世界の癌悪液質市場規模:作用機序別(食欲刺激剤、減量安定剤)
・世界の癌悪液質市場規模:地域別
・競争状況
・市場機会/将来の見通し
【レポートの概要】

The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period.

The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced globally. The COVID-19 pandemic also affected the global economy and showed a huge impact on the general hospital care functioning for non-COVID-19 patients in hospitals across the world.

According to the research article published in the British Journal of Nutrition, 2020, changes in the nutritional status and weight loss during hospitalization are largely reported in some populations, but it is not completely explored in COVID-19 patients. However, the symptoms and associated conditions of COVID-19 leads to nutritional status deterioration, leading to cachexia.

Also, cancer patients are at a higher risk of being infected with COVID-19, as cancer patients are immunocompromised and their ability to fight against the infection is very low compared to other individuals. Additionally, if a cancer patient develops a COVID-19 infection, there are higher chances of developing multiple organ-related complications or cachexia.

The increasing prevalence of cancer and cancer cachexia cases, along with the increasing investment in the research and development activities for the development of novel therapeutics in the treatment of cancer cachexia, are the major factors driving the market growth.

The global cancer burden is increasing, so cancer therapies must be modified according to regional and national priorities. As per the International Agency for Research on Cancer (IARC in December 2020, estimated that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. Hence, the increasing burden of cancers worldwide also increases the prevalence of cancer cachexia among cancer patients, which is characterized by systemic inflammation, negative protein and energy balance, and an involuntary loss of lean body mass.

Because of this factor, most of the major players are focused on R&D activities for the development of highly effective novel drugs in the treatment of cancer cachexia. This resulted in an increased pipeline of therapeutics that are waiting for approval and commercial launch post-approval. For instance, ClinicalTrials.gov reported that as of December 2020, there were a total of 134 studies that were conducted or were being conducted to develop drugs that treat cancer cachexia.

However, manufacturers of cancer cachexia drugs are discouraged from investing in the market because of the strict regulatory requirements and the long FDA approval procedure, which may impede the long-term growth of this market.

Key Market Trends

Appetite Stimulators is Expected to Grow Significantly in the Global Cancer Cachexia Market

Cancer patients frequently develop loss of appetite and weight loss. Unintended weight loss and anorexia (the loss of appetite or desire to eat) in patients with cancer is associated with decreased performance status, reduced response and tolerance to treatment, decreased survival, and reduced quality of life. Therefore, the increasing use of an appetite stimulant could be considered for patients who exhibit decreased appetite. The increasing prevalence of cancer cachexia cases is one of the major factors propelling the overall market’s growth.

According to the Oncology Nursing Society, appetite stimulants, such as dexamethasone, methylprednisolone, prednisolone, megestrol acetate, and medroxyprogesterone acetate, have been shown to increase the appetite and weight of patients suffering from cancer cachexia. Megestrol acetate is an appetite stimulant with progestational and antigonadotropic effects. In cancer patients with weight loss, megestrol acetate has been reported to have beneficial effects on appetite and results in a slight increase in weight, but it has not produced improvements in lean body mass or quality of life. Thus, their demand is expected to increase with the increase in the diagnosis of cancers.

Therefore, with the growing burden of cancer across the world, market players are investing steadily in innovative products and their R&D, which boosts the market growth.

For instance, in March 2020, Pfizer Inc., a global pharmaceutical major, launched a global 12-week open-label study which will explore how its drug PF-06946860 is tolerated in patients with cancer cachexia. Hence the factors mentioned above, helps the appetite stimulators segment is anticipated to achieve a high growth rate in the future.

North America is Expected to Dominate the Cancer Cachexia Market

North American is expected to dominate the market due to the high burden of cancer and cancer cachexia along with the presence of a large number of drug manufacturers and the advancing paradigm of care for cancer patients that is supporting the growth in this region. According to the estimates of Globocan 2020, there are around 195,499 new cases of cancer in Mexico. At the same time, approximately 90,222 deaths were recorded due to cancer in 2020 in Mexico.

According to Markus S. Anker, in the article Orphan disease status of cancer cachexia in the USA and the European Union: a systematic review’, published in 2019, in the 14 separately analyzed cancer types, the prevalence of cancer cachexia in the United States ranged between 11,300 (0.4/10 000, gastric cancer) and 92,000 patients (2.9/10000, lung cancer).

Advancements in novel technology for the treatment of cancer cachexia and a strong product pipeline for wasting syndrome have also helped in the growth of the cancer cachexia market in the region. Aveo Oncology, a United States-based biopharmaceutical company has developed AV-380, its first-in-class, potent, and humanized inhibitory antibody targeting GDF15, for the treatment of cancer cachexia, which is on track for IND application submission, with a planned Phase 1 clinical study for the first quarter of 2021.

Competitive Landscape

The majority of the cancer cachexia therapy drugs are being manufactured by a few key players. Some of the major players include Pfizer Inc., Merck & Co. Inc., Alder BioPharmaceuticals Inc., Aeterna Zentaris, and Bristol-Myers Squibb Company. Product launches, acquisitions, and R&D activities are key strategies adopted by players in the cancer cachexia market. Market leaders with more funds for research and a better distribution system have established their position in the market. For instance, A clinical study on the effect of medical Cannabidiol on lean body mass (cachexia) in patients receiving Oxaliplatin- or Paclitaxel-based chemotherapy was initiated by the University of Copenhagen, in collaboration with Zealand University Hospital, in December 2020.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

【レポートの目次】

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer Cachexia
4.2.2 Strong R&D and Product Pipeline
4.3 Market Restraints
4.3.1 Stringent Regulatory Requirements
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapeutics
5.1.1 Progestogens
5.1.2 Corticosteroids
5.1.3 Combination Therapy
5.1.4 Others
5.2 By Mechanism of Action
5.2.1 Appetite Stimulators
5.2.2 Weight Loss Stabilizers
5.3 Geography
5.3.1 North America
5.3.1.1 United States (By Therapeutics, and By Mechanism of Action)
5.3.1.2 Canada (By Therapeutics, and By Mechanism of Action)
5.3.1.3 Mexico (By Therapeutics, and By Mechanism of Action)
5.3.2 Europe
5.3.2.1 Germany (By Therapeutics, and By Mechanism of Action)
5.3.2.2 United Kingdom (By Therapeutics, and By Mechanism of Action)
5.3.2.3 France (By Therapeutics, and By Mechanism of Action)
5.3.2.4 Italy (By Therapeutics, and By Mechanism of Action)
5.3.2.5 Spain (By Therapeutics, and By Mechanism of Action)
5.3.2.6 Rest of Europe (By Therapeutics, and By Mechanism of Action)
5.3.3 Asia-Pacific
5.3.3.1 China (By Therapeutics, and By Mechanism of Action)
5.3.3.2 Japan (By Therapeutics, and By Mechanism of Action)
5.3.3.3 India (By Therapeutics, and By Mechanism of Action)
5.3.3.4 Australia (By Therapeutics, and By Mechanism of Action)
5.3.3.5 South Korea (By Therapeutics, and By Mechanism of Action)
5.3.3.6 Rest of Asia-Pacific (By Therapeutics, and By Mechanism of Action)
5.3.4 Middle East and Africa
5.3.4.1 GCC (By Therapeutics, and By Mechanism of Action)
5.3.4.2 South Africa (By Therapeutics, and By Mechanism of Action)
5.3.4.3 Rest of Middle East and Africa (By Therapeutics, and By Mechanism of Action)
5.3.5 South America
5.3.5.1 Brazil (By Therapeutics, and By Mechanism of Action)
5.3.5.2 Argentina (By Therapeutics, and By Mechanism of Action)
5.3.5.3 Rest of South America (By Therapeutics, and By Mechanism of Action)

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aeterna Zentaris
6.1.2 Aphios Corporation
6.1.3 Bristol-Myers Squibb Company
6.1.4 Pfizer Inc.
6.1.5 Helsinn Group
6.1.6 Merck KGaA
6.1.7 Artelo Biosciences Inc.
6.1.8 NGM Biopharmaceuticals
6.1.9 Aveo Oncology
6.1.10 Aavogen Inc.
6.1.11 Green Cross Wellbeing Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[癌悪液質の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆